NeoGenomics, Inc. (NEO) Stock Price & How to Invest

NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026.

What makes the stock interesting is arithmetic that has quietly changed shape. Second-quarter 2026 revenue of about $202 million grew roughly 11% year over year, but clinical test volume rose only about 2%; average revenue per clinical test climbed roughly 12% to about $515 as NGS revenue grew about 26%. Adjusted gross margin expanded about 260 basis points, adjusted EBITDA rose about 36% to roughly $14 million, and management raised full-year 2026 guidance to roughly $802 million to $806 million of revenue with adjusted EBITDA of roughly $56 million to $58 million. GAAP profitability remains absent, with a trailing twelve-month net loss near $53 million, and the balance sheet now carries about $385 million of convertible principal against roughly $146 million of cash and short-term investments after a June 2026 refinancing. Anyone weighing NEO is essentially asking whether the price and mix tailwind can continue long enough to close that gap.

GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation. Reimbursement concentration is the structural exposure: Medicare through MolDx and commercial payors set the prices behind that rising revenue-per-test figure, and evolving regulation of laboratory developed tests could raise the compliance cost of the same menu. Growth is currently priced rather than volume driven, since clinical test count rose only about 2% year over year, so any payor pushback on pricing would hit revenue quickly. On litigation, a purported securities class action captioned Goldenberg v. NeoGenomics (S.D.N.Y., No. 22-cv-10314, filed December 16, 2022, covering purchases between February 27, 2020 and April 26, 2022) was dismissed with prejudice on March 13, 2026, and the plaintiff appealed to the Second Circuit on April 10, 2026; related shareholder derivative actions in Nevada, Florida and New York remain stayed pending that appeal, and the company states the outcome is not currently estimable. Finally, goodwill and intangibles of roughly $795 million sit on a $1.35 billion balance sheet alongside about $385 million of convertible principal, and the 2025 InVisionFirst-Lung write-down showed that impairment of acquired assets is a live possibility.

9 analysts publish price targets on NEO, averaging $19.72 against a $16.16 price as of August 2026, or +22.0%. The published targets run from $16.00 to $35.00, a wide spread, and the ratings split 8 buy, 4 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NEO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on NeoGenomics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Mix shift into NGS carries the revenue line. Next-generation sequencing revenue grew roughly 26% year over year in the second quarter of 2026 while total clinical volume rose about 2%. The most optimistic published target, $35.00, assumes this works close to its best case.

The case against. GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation. The most pessimistic target, $16.00, is roughly what NEO is worth if this bites instead.

Read the full bull and bear case on NEO, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NeoGenomics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$766M (four quarters ended June 30, 2026)
• Q2 2026 revenue: ~$202M, up ~11% year over year
• Market cap: ~$2.1B (~$16 per share on ~128.5M shares)
• Price to sales: ~2.7x trailing; enterprise value ~$2.3B, or ~3.0x sales
• GAAP result: TTM net loss ~$53M; Q2 2026 net income ~$2M including an ~$11M debt extinguishment gain
• FY2026 guidance: Revenue ~$802M to ~$806M; adjusted EBITDA ~$56M to ~$58M

With no trailing earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.7 times trailing revenue and roughly 40 times the midpoint of guided 2026 adjusted EBITDA. That second figure only looks reasonable if margin expansion continues for several more years, which is the crux of the debate on the name. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from $5.94 to $16.92 over the past 52 weeks.

Other names that sit close to NEO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NEO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NEO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NEO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

NeoGenomics is a real, growing oncology testing business trading around 2.7 times trailing sales while still losing money on a GAAP basis, so it suits an investor tracking margin execution and reimbursement decisions rather than one looking for present earnings.

Whether NEO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NEO a buy or a sell?, and where the stock could go from here in the NEO stock forecast.

For income investors, whether NEO pays a dividend and how the payout looks is covered in does NEO pay a dividend? And to weigh NEO against a peer, read the full side-by-side comparisons: NEO vs GH and NEO vs CAI.